Clinical Trials Logo

Lymphoma Leukemia clinical trials

View clinical trials related to Lymphoma Leukemia.

Filter by:
  • None
  • Page 1

NCT ID: NCT05114837 Not yet recruiting - Lymphoma Leukemia Clinical Trials

Ph I/II Study of CAR19 Regulatory T Cells (CAR19-tTreg) for R/R CD19+ B-ALL

Start date: September 2024
Phase: Phase 1/Phase 2
Study type: Interventional

This is a single-center, single-arm, interventional phase I/II trial to evaluate the safety profile and potential efficacy of allogeneic CAR19 regulatory T cells (CAR19-tTreg) in adults with relapsed/refractory (R/R) CD19+ B Acute Lymphocytic Leukemia (B-ALL). The study consists of two components. The dose finding component is a modified version of a Phase I trial and the extended component is a modified Phase II trial.

NCT ID: NCT03975205 Not yet recruiting - Lymphoma Leukemia Clinical Trials

To Study the Concentration Level of, Doxil, and Doxorubicin at Various Time Frames

Doxil
Start date: July 1, 2019
Phase: Early Phase 1
Study type: Interventional

Doxil or Doxorubicin to be administered was administered in a dose of 50 mg/m2 as infusion over 15 minutes. Blood samples to be obtained at 0, 1, 2, 3, 4, 8, 12, 24, 48 and 72 hours

NCT ID: NCT03811457 Completed - Lymphoma Leukemia Clinical Trials

Immunotherapy With CD19 CAR T-cells in Patients With Relapsed or Refractory CD19+ Leukemia and Lymphoma

Start date: June 1, 2017
Phase: N/A
Study type: Interventional

B cell malignancies comprise a heterogeneous group of neoplasms including a vast majority of non-Hodgkin's lymphomas (NHL), lymphoblastic leukemias (ALL) and chronic lymphocytic leukemias (CLL). Current treatments for B cell malignancies include chemotherapy, radiation therapy, bone marrow transplantation, and peripheral blood stem cell transplantation. Despite these treatment modalities, most patients will remain incurable. Welgenaleucel (UWC19) is a CD19-directed genetically-modified autologous immunotherapy. This study is designed to evaluate safety and feasibility of administering Welgenaleucel (UWC19) transduced with anti-CD19 lentiviral vector to patients with advanced refractory hematologic malignancies, including DLBCL and ALL.